Marc Stapley serves as the Chief Executive Officer of Veracyte Inc., a leading genomic diagnostics company focused on improving patient care through advanced diagnostic solutions. With a robust background in the life sciences industry, Stapley has been instrumental in guiding Veracyte's growth and innovation. Before joining Veracyte in 2012 as Chief Operating Officer and later becoming CEO in 2013, he held significant roles at companies such as Affymetrix and Beckman Coulter. His career is marked by a strong track record in strategic leadership and operational excellence, which have been crucial in steering Veracyte towards its mission of transforming cancer care. Under Stapley's leadership, Veracyte has expanded its portfolio of diagnostic tests and enhanced its market presence, notably through the development and commercialization of the Afirma and Prosigna tests. These tests have been pivotal in providing physicians with more precise diagnostic tools to guide treatment decisions for patients with thyroid cancer and breast cancer, respectively. Stapley's strategic vision has also led to the company's successful IPO in 2013 and several key acquisitions that have bolstered Veracyte's capabilities in genomic diagnostics. His commitment to advancing healthcare through genomics is evident in his ongoing efforts to foster innovation and collaboration within the industry. As CEO, Marc Stapley continues to drive Veracyte's mission to provide clarity and confidence to patients and physicians through advanced diagnostic solutions. His leadership is characterized by a focus on scientific excellence, patient-centric innovation, and sustainable growth. Under his guidance, Veracyte is well-positioned to meet the evolving needs of the healthcare landscape and to make significant contributions to personalized medicine.